1,356 research outputs found
The Calculation of the Bending Moment Response of a Typical Launch Vehicle Using Generalized Power Spectral Techniques
Bending moment response calculation of launch vehicle using generalized power spectral technique
Determination of the survival probability of a launch vehicle rising through a random wind field
Survival probability of rising launch vehicle subjected to wind shear loads - statistical load survey method, and wind profile analyses for design consideration
Redshift clustering in the Hubble Deep Field
We present initial results from a redshift survey carried out with the Low
Resolution Imaging Spectrograph on the 10~m W. M. Keck Telescope in the Hubble
Deep Field. In the redshift distribution of the 140 extragalactic objects in
this sample we find 6 strong peaks, with velocity dispersions of
{\kms}. The areal density of objects within a particular peak, while
it may be non-uniform, does not show evidence for strong central concentration.
These peaks have characteristics (velocity dispersions, density enhancements,
spacing, and spatial extent) similar to those seen in a comparable redshift
survey in a different high galactic latitude field (Cohen et al 1996),
confirming that the structures are generic. They are probably the high redshift
counterparts of huge galaxy structures (``walls'') observed locally.Comment: 14 pages, including 2 figures, to appear in ApJ Letter
Caltech Faint Galaxy Redshift Survey X: A Redshift Survey in the Region of the Hubble Deep Field North
A redshift survey has been carried out in the region of the Hubble Deep Field
North using the Low Resolution Imaging Spectrograph at the Keck Observatory.
The resulting redshift catalog, which contains 671 entries, is a compendium of
our own data together with published LRIS/Keck data. It is more than 92%
complete for objects, irrespective of morphology, to mag in the HDF
itself and to mag in the Flanking Fields within a diameter of 8 arcmin
centered on the HDF, an unusually high completion for a magnitude limited
survey performed with a large telescope. A median redshift is reached
at .
Strong peaks in the redshift distribution, which arise when a group or poor
cluster of galaxies intersect the area surveyed, can be identified to in this dataset. More than 68% of the galaxies are members of these
redshift peaks. In a few cases, closely spaced peaks in can be resolved
into separate groups of galaxies that can be distinguished in both velocity and
location on the sky.
The radial separation of these peaks in the pencil-beam survey is consistent
with a characteristic length scale for the their separation of 70 Mpc
in our adopted cosmology (, ). Strong
galaxy clustering is in evidence at all epochs back to . (abstract
abridged)Comment: Accepted to the ApJ. This version contains all the figures and
tables. 2 minor typos in table 2b correcte
Clinical use of HIV integrase inhibitors : a systematic review and meta-analysis
Background: Optimal regimen choice of antiretroviral therapy is essential to achieve long-term clinical success. Integrase inhibitors have swiftly been adopted as part of current antiretroviral regimens. The purpose of this study was to review the evidence for integrase inhibitor use in clinical settings.
Methods: MEDLINE and Web-of-Science were screened from April 2006 until November 2012, as were hand-searched scientific meeting proceedings. Multiple reviewers independently screened 1323 citations in duplicate to identify randomized controlled trials, nonrandomized controlled trials and cohort studies on integrase inhibitor use in clinical practice. Independent, duplicate data extraction and quality assessment were conducted.
Results: 48 unique studies were included on the use of integrase inhibitors in antiretroviral therapy-naive patients and treatment-experienced patients with either virological failure or switching to integrase inhibitors while virologically suppressed. On the selected studies with comparable outcome measures and indication (n = 16), a meta-analysis was performed based on modified intention-to-treat (mITT), on-treatment (OT) and as-treated (AT) virological outcome data. In therapy-naive patients, favorable odds ratios (OR) for integrase inhibitor-based regimens were observed, (mITT OR 0.71, 95% CI 0.59-0.86). However, integrase inhibitors combined with protease inhibitors only did not result in a significant better virological outcome. Evidence further supported integrase inhibitor use following virological failure (mITT OR 0.27; 95% CI 0.11-0.66), but switching to integrase inhibitors from a high genetic barrier drug during successful treatment was not supported (mITT OR 1.43; 95% CI 0.89-2.31). Integrase inhibitor-based regimens result in similar immunological responses compared to other regimens. A low genetic barrier to drug-resistance development was observed for raltegravir and elvitegravir, but not for dolutegravir.
Conclusion: In first-line therapy, integrase inhibitors are superior to other regimens. Integrase inhibitor use after virological failure is supported as well by the meta-analysis. Careful use is however warranted when replacing a high genetic barrier drug in treatment-experienced patients switching successful treatment
Genetic Factors in Seizures: A Population-Based Study of 47,626 US, Norwegian and Danish Twin Pairs
Evaluation of a complex intervention (Engager) for prisoners with common mental health problems, near to and after release: study protocol for a randomised controlled trial.
INTRODUCTION: The 'Engager' programme is a 'through-the-gate' intervention designed to support prisoners with common mental health problems as they transition from prison back into the community. The trial will evaluate the clinical and cost-effectiveness of the Engager intervention. METHODS AND ANALYSIS: The study is a parallel two-group randomised controlled trial with 1:1 individual allocation to either: (a) the Engager intervention plus standard care (intervention group) or (b) standard care alone (control group) across two investigation centres (South West and North West of England). Two hundred and eighty prisoners meeting eligibility criteria will take part. Engager is a person-centred complex intervention delivered by practitioners and aimed at addressing offenders' mental health and social care needs. It comprises one-to-one support for participants prior to release from prison and for up to 20 weeks postrelease. The primary outcome is change in psychological distress measured by the Clinical Outcomes in Routine Evaluation-Outcome Measure at 6 months postrelease. Secondary outcomes include: assessment of subjective met/unmet need, drug and alcohol use, health-related quality of life and well-being-related quality of life measured at 3, 6 and 12 months postrelease; change in objective social domains, drug and alcohol dependence, service utilisation and perceived helpfulness of services and change in psychological constructs related to desistence at 6 and 12 months postrelease; and recidivism at 12 months postrelease. A process evaluation will assess fidelity of intervention delivery, test hypothesised mechanisms of action and look for unintended consequences. An economic evaluation will estimate the cost-effectiveness. ETHICS AND DISSEMINATION: This study has been approved by the Wales Research Ethics Committee 3 (ref: 15/WA/0314) and the National Offender Management Service (ref: 2015-283). Findings will be disseminated to commissioners, clinicians and service users via papers and presentations. TRIAL REGISTRATION NUMBER: ISRCTN11707331; Pre-results
Recommended from our members
Experimental Transport Benchmarks for Physical Dosimetry to Support Development of Fast-Neutron Therapy with Neutron Capture Augmentation
The Idaho National Laboratory (INL), the University of Washington (UW) Neutron Therapy Center, the University of Essen (Germany) Neutron Therapy Clinic, and the Northern Illinois University(NIU) Institute for Neutron Therapy at Fermilab have been collaborating in the development of fast-neutron therapy (FNT) with concurrent neutron capture (NCT) augmentation [1,2]. As part of this effort, we have conducted measurements to produce suitable benchmark data as an aid in validation of advanced three-dimensional treatment planning methodologies required for successful administration of FNT/NCT. Free-beam spectral measurements as well as phantom measurements with Lucite{trademark} cylinders using thermal, resonance, and threshold activation foil techniques have now been completed at all three clinical accelerator facilities. The same protocol was used for all measurements to facilitate intercomparison of data. The results will be useful for further detailed characterization of the neutron beams of interest as well as for validation of various charged particle and neutron transport codes and methodologies for FNT/NCT computational dosimetry, such as MCNP [3], LAHET [4], and MINERVA [5]
- …